Clinical Trials Sponsored by Elios Therapeutics, LLC

Total 410 results

Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Grifols Therapeutics LLC
Instituto Grifols, S.A.

Active, not recruiting

Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites (PRECIOSA)

Decompensated Cirrhosis and Ascites

United States, Spain, Denmark, Belgium, Germany, Italy, Canada, Hungary, Poland, Bosnia and Herzegovina, Bulgaria, France, Serbia, United Kingdom
Arrys Therapeutics
Merck Sharp & Dohme LLC

Completed

Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

Microsatellite Stable Colorectal Cancer

United States
Instituto Grifols, S.A.

Withdrawn

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis

Hypofibrinogenemia | Congenital Afibrinogenemia

India, Turkey, Lebanon, United States, Bulgaria
NYU Langone Health
JDS Therapeutics, LLC

Completed

A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause

Genitourinary Syndrome of Menopause (GSM)

United States
Instituto Grifols, S.A.
Instituto Grifols, S.A.

Completed

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

Excessive Bleeding During Surgery

Germany, United States, Bulgaria, France, Hungary, Romania, Serbia, United Kingdom, Canada, Sweden
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

Japan
Instituto Grifols, S.A.

Completed

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19

COVID-19

Spain
Instituto Grifols, S.A.

Completed

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

COVID-19

Spain
Instituto Grifols, S.A.

Completed

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

COVID-19

Spain
Lotus Clinical Research, LLC
CerSci Therapeutics

Unknown

Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers

Surgery | Pain, Acute | Acute Pain | Neuropathy

United States
Lotus Clinical Research, LLC
CerSci Therapeutics

Completed

Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers

Surgery | Pain, Acute | Acute Pain | Neuropathy

United States
Grifols Therapeutics LLC
Covance; Clinipace Worldwide

Completed

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Cardiac Surgery | Cardiopulmonary Bypass

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Lipid Metabolism, Inborn Errors | Hypobetalipoproteinemias | Hypolipoproteinemias | Hypolipopro... and other conditions

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Hypercholesterolemia | Coronary Heart Disease

South Africa, Germany, United States, United Kingdom, Canada, Czech Republic
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

Healthy Volunteer

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Astellas Pharma Inc
Perseid Therapeutics LLC

Completed

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Rheumatoid Arthritis

United States
Grifols Therapeutics LLC
Instituto Grifols, S.A.

Recruiting

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% (APACHE)

Acute-On-Chronic Liver Failure

United States, United Kingdom, Spain, Germany, Italy, Belgium, France, Austria, Denmark, Portugal
Highlight Therapeutics
Merck Sharp & Dohme LLC

Active, not recruiting

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203)

Melanoma

Spain, France
iTeos Therapeutics
Merck Sharp & Dohme LLC

Active, not recruiting

First-in-Human Study of EOS100850 in Patients With Cancer

Solid Tumor, Adult

Spain, United States, France, Korea, Republic of, Belgium, United Kingdom
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Alpha1-Antitrypsin Deficiency

Japan
Grifols Therapeutics LLC
Instituto Grifols, S.A.

Completed

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia (IG0902)

Congenital Afibrinogenemia

India, United States, Italy, Lebanon
Rapa Therapeutics LLC
Hackensack Meridian Health

Terminated

RAPA-501-Allo Therapy of COVID-19-ARDS

Severe COVID-19 Disease

United States
Arrys Therapeutics
Merck Sharp & Dohme LLC

Terminated

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Non-small Cell Lung Cancer Adenocarcinoma

United States
BriaCell Therapeutics Corporation
Cancer Insight, LLC

Completed

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Breast Neoplasm | Breastcancer

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects (ASSIST)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Metabolic Disorder

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease (RADICHOL II)

Coronary Artery Disease | Heterozygous Familial Hypercholesterolemia

United States, Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Canada, Brazil, Taiwan, Singapore, South Africa, United Kingdom
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia (RADICHOL 1)

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Taiwan, Brazil, Canada, South Africa, United Kingdom, Singapore
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Healthy Volunteer

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Hypercholesterolemia

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Hypercholesterolemia

Netherlands, United States
Mediar Therapeutics
ICON plc

Recruiting

A First-in-Human Safety Trial of MTX-463

Healthy

United States
Therapeutic Concepts
Janssen Scientific Affairs, LLC

Unknown

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)

HIV Positive

United States
ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia
Werewolf Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Rambam Health Care Campus
Constant Therapeutics LLC

Recruiting

Angiotensin 1-7 as a Therapy in the Treatment of COVID-19

COVID-19

Israel
Rapa Therapeutics LLC
Medical College of Wisconsin

Recruiting

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Relapsed, Refractory Multiple Myeloma

United States
RAPT Therapeutics, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Advanced Cancer

Hong Kong, United States, Australia, Korea, Republic of, Taiwan, Thailand
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma

United States
Rare Disease Research, LLC
Sarepta Therapeutics, Inc.

Terminated

An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, United Kingdom, France, Spain, Israel, Romania, Korea, Republic of, Australia, Canada, New Zealand, Hungary, Georgia, Former Serbia and Montenegro, Peru
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Gastrointestinal Stromal Tumor (GIST)

United States
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Completed

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Hepatitis C, Chronic
Frantz Viral Therapeutics, LLC
The Cleveland Clinic

Recruiting

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) (ART-VIN IIB)

Vulvar Diseases | HPV Infection | Vulvar HSIL | High Grade Intraepithelial Neoplasia | HPV Disease | Pre-Cancerous Dysplasia | Vin II | Vin III | VIN, Usual Type | VIN 2 of Usual Type | VIN 3 of Usual Type | VIN Grade 2 | VIN Grade 3

United States
BioXcel Therapeutics Inc
Lotus Clinical Research, LLC

Recruiting

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Schizophrenia | Bipolar Disorder | Schizo Affective Disorder | Agitation,Psychomotor | Schizophreniform Disorders

United States

Clinical Trials Sponsored by Elios Therapeutics, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations